Zenotech Laboratories Ltd

Zenotech Laboratories has announced its financial results for Q3 FY24-25, reporting net sales of Rs 11.24 crore, the highest in five quarters. Profit Before Tax reached Rs 2.12 crore, showing growth compared to previous quarters, while Profit After Tax for the half-year declined significantly year on year.

Zenotech Laboratories has undergone a revision in its stock evaluation by MarketsMOJO, reflecting a significant shift in its financial performance metrics following disappointing results for September 2024. The company has been added to MarketsMOJO's list, indicating ongoing scrutiny of its market position amid challenges in revenue growth and liquidity concerns.

Zenotech Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its high management efficiency and strong financial position. While the stock is currently in a Mildly Bullish range, negative results in September 2024 have affected its profits and net sales. Despite this, the majority shareholders' confidence and potential for future growth make it a stock to watch.

Zenotech Laboratories, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to its negative financial results in September 2024. The company's PAT has decreased by -68.21% and net sales by -5.8%, while its operating cash flow is at its lowest. Despite a 28.33% return in the past year, the stock is trading at a discount and domestic mutual funds hold 0% of the company. However, Zenotech Laboratories has a low debt to equity ratio and a mildly bullish technical outlook. Investors should carefully consider all aspects before making any investment decisions.

Zenotech Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its high management efficiency and low Debt to Equity ratio. However, the company has experienced negative results in September 2024 and has a Very Expensive valuation. Domestic mutual funds hold a small stake, possibly indicating a lack of confidence. Investors should carefully consider all factors before investing.

Zenotech Laboratories, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to its negative financial results in September 2024. The company's profits have fallen by -56.34% and its net sales have decreased by -5.8%. Its expensive valuation and low domestic mutual fund ownership also raise concerns. Technical indicators suggest a mildly bullish trend.

Zenotech Laboratories, a microcap pharmaceutical company, has reported a decline in its financial performance for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO, with a significant drop in its overall score and a decrease in key financial indicators such as PBT, PAT, and net sales. This raises concerns about the company's future prospects and calls for a cautious approach towards its stock.

Zenotech Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 11, 2024. The stock has outperformed its sector by 3.99% and gained 53.5% in the last 7 days. With a strong performance in the past year and a 'Hold' call from MarketsMOJO, the company shows potential for further growth.

Zenotech Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 10, 2024. With a 32.59% increase in returns over the past 6 days and a 'Hold' call from MarketsMOJO, the company's strong performance and positive trend make it a promising investment option.

Zenotech Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 9th, 2024. The stock has outperformed its sector by 5.04% and gained 19.91% in the last 5 days. With a 'Hold' recommendation from MarketsMOJO, the company has shown strong growth and potential for returns.

Zenotech Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 6, 2024. The stock has been on an upward trend for the past four days, outperforming the sector by 11.88%. Despite high volatility, the stock is currently trading above its moving averages, indicating potential for growth.

Zenotech Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its high management efficiency and strong ability to service debt. The stock is currently in a Mildly Bullish range with positive technical trends, but its recent results and expensive valuation may be cause for concern.

Zenotech Laboratories, a microcap pharmaceutical company, has reported a flat performance in the quarter ending June 2024, with a -3 score, an improvement from the previous quarter. However, the company's PAT for the first half of the year has decreased by 61.84% compared to last year. Investors are advised to carefully consider the company's financial performance before making any investment decisions.

Zenotech Laboratories, a microcap pharmaceutical company, has been downgraded to a 'Strong Sell' by MarketsMOJO due to its negative financial results in the quarter ending March 2024. The company's profits have fallen by -76.6%, with a low PAT(Q) of Rs 0.66 crore and NET SALES(Q) of Rs 9.11 crore. Technical trends also show a bearish trend, with the stock trading at a discount compared to historical valuations. Despite some positive factors, caution is advised for potential investors.

Zenotech Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its high management efficiency and strong ability to service debt. The stock is currently in a Mildly Bullish range with positive technical factors. While the majority shareholders are promoters, the company reported negative results in March 2024. With a ROE of 9.2, the stock has a Very Expensive valuation but is currently trading at a discount. However, it has underperformed the market in the last year. Investors should carefully consider these factors before investing in Zenotech Laboratories.

Zenotech Laboratories, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO after reporting negative results in the quarter ending March 2024. The company's profits have fallen by -76.6%, with a -2.85% return since May 9, 2024. Multiple factors indicate a bearish outlook for the stock, despite its high management efficiency and low debt.

Zenotech Laboratories, a microcap pharmaceutical company, received a 'Hold' rating from MarketsMOJO on May 3rd, 2024. The company's low debt and bullish technical trends are positive factors, but its recent negative results and underperformance in the market may be a cause for caution. Majority shareholders are promoters, providing stability and growth potential.

Zenotech Laboratories, a microcap pharmaceutical company, reported negative financial results for the quarter ending March 2024. The company's stock has been given a 'Sell' call by MarketsMOJO due to a decline in profit before tax, profit after tax, net sales, and operating profit. This is the lowest performance in the last five quarters.

Zenotech Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on January 16, 2024. The company's stock call has been rated as 'Hold' by MarketsMOJO, with its stock trading higher than its moving averages and outperforming the Sensex. This indicates a positive outlook for the company in the pharmaceutical industry.